What is Engeneic?
Engeneic is a clinical-stage biotechnology firm dedicated to the research, development, and manufacturing of targeted anti-cancer therapies. At the core of its operations is the innovative EDV nanocell platform, a first-in-class cyto-immunotherapy technology designed to deliver potent therapeutic agents directly to tumor sites while simultaneously activating the patient's immune system. This dual-action mechanism represents a significant departure from traditional chemotherapy, aiming to minimize systemic toxicity while maximizing efficacy. Currently, the company is focused on the clinical validation of its EGFR-targeted EDV nanocells, with active trials evaluating safety and therapeutic outcomes in patients suffering from advanced solid tumors. By bridging the gap between nanotechnology and immunology, Engeneic is working to redefine the treatment paradigm for complex oncological conditions.
How much funding has Engeneic raised?
Engeneic has raised a total of $18M across 3 funding rounds:
Private Equity
$1M
Series A
$7M
Series B
$10M
Private Equity (2011): $1M, investors not publicly disclosed
Series A (2014): $7M, investors not publicly disclosed
Series B (2014): $10M supported by GRT Capital Partners LLC and Foley Ventures
Key Investors in Engeneic
GRT Capital Partners LLC
GRT Capital Partners is an investment firm focused on identifying and supporting high-growth companies with significant market potential.
Foley Ventures
Foley Ventures is an independent venture capital fund that invests in a diverse range of industries, including software services, healthcare, biotechnology, and more.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Engeneic?
With the recent capital injection, Engeneic is well-positioned to advance its clinical roadmap and refine its manufacturing capabilities for the EDV nanocell platform. The strategic focus will likely remain on the successful completion of Phase I/IIa trials, which serve as a critical milestone for future regulatory submissions and potential commercialization partnerships. As the company moves deeper into the clinical development lifecycle, the emphasis will shift toward scaling production processes and expanding the therapeutic scope of its nanocell technology to address a broader range of solid tumor indications. Continued investment will be essential to maintain the momentum required to navigate the rigorous regulatory environment and bring these novel therapies to market, ultimately aiming to improve patient outcomes in the oncology space.
See full Engeneic company page
